BioNTech Announces Third Quarter 2022 Financial Results and Corporate Update

BioNTech updates its 2022 financial guidance, raising its COVID-19 vaccine revenue estimate to the upper end of the original range: €16 – 17 billion
(previously: €13 – 17 billion). The updated guidance reflects the shipment of the Omicron-adapted bivalent vaccine boosters, which started early in
September and is expected to continue throughout the fourth quarter of 2022 as well as higher prices and a positive foreign currency effect.